Retrospective analysis reveals links between metabolism-related genes, prognosis, and immune microenvironment in endometrial carcinoma.
Background Endometrial carcinoma is a clinically complex gynaecologic malignancy exhibiting significant molecular heterogeneity. This heterogeneity manifests as marked variability in clinical outcomes and heterogeneous therapeutic responses to emerging treatment modalities, particularly to immune checkpoint inhibitors. Metabolic reprogramming has been implicated in tumour progression and immune evasion in endometrial carcinoma. However, the prognostic implications of metabolism-related genes and their interaction with the tumour immune microenvironment remain insufficiently characterised.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: